Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1937
TNBC
Basal A
Nutlin 3a
MDM2
MDM2
7452.066
uM
29.47080
58.06260
-0.1140 -1.0000 1.6201 0.1213
0.9753
1.4723
HCC1937
TNBC
Basal A
Nutlin 3a
MDM2
MDM2
7453.066
uM
19.2410
18.05470
0.1353 0.1339 4.8969 0.0485
0.9855
1.3901
HCC1937
TNBC
Basal A
Olomoucine II
CDK1
CDK
11849.147
uM
7.96540
8.91870
-0.2658 -0.2648 3.7594 0.2354
0.9962
1.3461
HCC1937
TNBC
Basal A
Omipalisib
PI3K
PI3K
7453.086
uM
0.03125
0.07221
-0.4222 -0.3479 0.6306 0.6303
0.9877
1.4238
HCC1937
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
7832.011
uM
2.9990
23.37050
-0.7894 -1.0000 0.5351 0.5793
0.9709
1.4385
HCC1937
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
7834.075
uM
11.99920
70.62470
-0.4847 -0.9291 0.5925 0.3917
0.9881
2.0182
HCC1937
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
10262.021
uM
10.13520
27.94670
-0.9380 -1.0000 1.0831 0.4678
0.9912
0.6806
HCC1937
TNBC
Basal A
Oxamflatin
HDAC
HDAC
11849.147
uM
1.80720
3.47010
-0.8976 -0.9698 1.6528 0.4724
0.9912
1.3461
HCC1937
TNBC
Basal A
PD 98059
MEK
MAPK
11849.159
uM
32.36610
1000.00000
0.3158 -0.6741 0.2488 0.2308
0.8570
1.2484
HCC1937
TNBC
Basal A
PD173074
FGFR1/3
RTK
7453.093
uM
7.77590
8.10660
-0.1145 -0.1155 4.9896 0.0831
0.9926
1.5872
HCC1937
TNBC
Basal A
PD184352
MEK
MAPK
11849.155
uM
inf
998.67740
0.8103 0.5512 0.1317 0.0991
0.6028
1.4975
HCC1937
TNBC
Basal A
PD184352
MEK
MAPK
11849.155
uM
inf
998.67740
0.8103 0.5512 0.1317 0.0991
0.6028
1.4975
HCC1937
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7453.095
uM
inf
inf
0.9591 0.9591 0.0000 0.0882
0.1205
1.6395
HCC1937
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7452.095
uM
inf
inf
0.4951 0.4951 0.0000 0.0433
0.3803
1.7316
HCC1937
TNBC
Basal A
PS-1145
IKK
NFKB
7453.065
uM
inf
inf
0.8929 0.8929 0.0000 0.0272
0.2991
1.6649
HCC1937
TNBC
Basal A
Purvalanol A
CDK1
CDK
7453.067
uM
inf
inf
1.0249 1.0249 0.0000 -0.0351
-2.6870
1.5080
HCC1937
TNBC
Basal A
Purvalanol A
CDK1
CDK
7452.067
uM
16.91250
10.82620
0.3707 0.4463 5.0000 0.1121
0.9632
1.7112
HCC1937
TNBC
Basal A
SB-3CT
MMP2/9
MMP
11849.144
uM
inf
23.07470
0.6766 0.6764 4.9727 0.0269
0.8728
1.4131
HCC1937
TNBC
Basal A
Selumetinib
MEK
MAPK
11849.155
uM
inf
0.09005
0.8273 0.8288 1.0107 0.0792
0.8095
1.4975
HCC1937
TNBC
Basal A
Sigma A6730
AKT
AKT
11849.158
uM
11.40840
18.59730
-0.9207 -1.0000 2.2482 0.2623
0.9849
1.4054
HCC1937
TNBC
Basal A
Sirolimus
MTOR
MTOR
7834.068
uM
2.71990
54.52920
-0.5448 -1.0000 0.3664 0.4095
0.7935
2.0420
HCC1937
TNBC
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7453.084
uM
inf
inf
1.0008 1.0008 0.0000 -0.0055
-0.0025
1.5592
HCC1937
TNBC
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7452.084
uM
21.00610
32.1780
-0.8452 -0.6562 1.9656 0.4290
0.9750
1.6800
HCC1937
TNBC
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7453.067
uM
inf
inf
-0.8500 -0.8500 0.0000 0.2391
0.4179
1.5080
HCC1937
TNBC
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7452.067
uM
6.77240
10.4640
-0.9429 -0.9418 2.4342 0.4021
0.9993
1.7112